ORCID Profile
0000-0002-9263-8567
Current Organisation
University of Tasmania
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Oxford University Press (OUP)
Date: 03-01-2013
DOI: 10.1039/C2IB20206A
Abstract: Although attempts have been made to unveil protein-protein and host-pathogen interactions based on molecular insights of important biological events and pathogenesis in various organisms, these efforts have not yet been reported in Corynebacterium pseudotuberculosis (Cp), the causative agent of Caseous Lymphadenitis (CLA). In this study, we used computational approaches to develop common conserved intra-species protein-protein interaction (PPI) networks first time for four Cp strains (Cp FRC41, Cp 316, Cp 3/99-5, and Cp P54B96) followed by development of a common conserved inter-species bacterial PPI using conserved proteins in multiple pathogens (Y. pestis, M. tuberculosis, C. diphtheriae, C. ulcerans, E. coli, and all four Cp strains) and E. Coli based experimentally validated PPI data. Furthermore, the interacting proteins in the common conserved inter-species bacterial PPI were used to generate a conserved host-pathogen interaction (HP-PPI) network considering human, goat, sheep, bovine, and horse as hosts. The HP-PPI network was validated, and acetate kinase (Ack) was identified as a novel broad spectrum target. Ceftiofur, penicillin, and two natural compounds derived from Piper betel were predicted to inhibit Ack activity. One of these Piper betel compounds found to inhibit E. coli O157:H7 growth similar to penicillin. The target specificity of these betel compounds, their effects on other studied pathogens, and other in silico results are currently being validated and the results are promising.
Publisher: Biomedical Informatics
Date: 30-09-2014
Publisher: University Nove de Julho
Date: 2017
DOI: 10.5585/IJI
Publisher: thinkBiotech, LLC
Date: 16-01-2017
DOI: 10.5912/JCB756
Abstract: Induced Pluripotent Stem Cells (IPSCs) are a kind of adult cells that have been genetically reprogrammed to become different cell types. Differentiated cells can be reprogrammed to an embryonic-like state by transfer of nuclear contents into oocytes or by fusion with embryonic stem cells. IPSCs technology was pioneered by Shinya Yamanaka from Kyoto University. This breakthrough has inspired researchers to start working around IPSC technology. James Thomson from University of California has developed IPS cell lines derived from Human Somatic Cells. Subsequently, he also established a large scale human IPSC manufacturing company named Cellular Dynamics International. Thus, increasing interest in the commercial exploitation of IPSCs patents has lead us to look into the patent portfolios of top three patent assignees in IPSC technology. In this study, we have discussed technological patent trends and multiple factors which reflect the competitive scenario between the top assignees of IPSC technology. Our conclusions suggest that Kyoto University led by inventor Shinya Yamanaka is the leader of IPSC technology. However, patent-product linkage analysis suggests that Cellular Dynamics International led by inventor James Thomson may surpass Kyoto University in near future.
Publisher: thinkBiotech, LLC
Date: 27-08-2018
DOI: 10.5912/JCB845
Abstract: Patenting medical therapeutic methods has become one of the toughest tasks for inventors and scientists in some jurisdictions where these methods are excluded from patentable subject matter. There are recent amendments by different countries in relation to patentability aspects of Therapeutic methods. In this scenario, analysis of these recent amendments would provide a path for researchers in the field to identify whether their inventions are considered as patentable subject matter. Our analysis sheds some light on different statutes and regulations of major jurisdictions on the patentable subject matter and patentability aspects of therapeutic methods. Furthermore, we have identified that most of the jurisdictions restrict inventors in patenting therapeutic methods. However, some countries such as United States and Australia allow patents related to therapeutic methods. We think adapting different strategies that are provided in this article would help researchers, inventors and patent attorneys in patenting the inventions related to therapeutic methods. Moreover, while applying the provided strategies, it is suggested that inventors should draft the patent claims by keeping a note of different statutes and regulations of countries in which they are interested to file the patent applications.
Publisher: thinkBiotech, LLC
Date: 27-08-2018
DOI: 10.5912/JCB831
Abstract: Patenting bioinformatic inventions has become a ride on the rail to the scientists and inventors. Specifically in bioinformatics, drafting an invention in bounds of patentability criteria is one the most critical task for an inventor to protect his invention. As bioinformatics is a budding field of science, patentable subject matter in bioinformatics was not specifically defined by most of the patent offices in the world. In this regard, we have tried to explain patentable subject matter in bioinformatics by classifying bioinformatics into different subject fields. Additionally, we have tried to trace out patentable subject matter for bioinformatic inventions based on country-specific patentability standards and granted bioinformatic patents of US, Europe, India, Canada and Australia.
Location: India
No related grants have been discovered for Pratap Devarapalli.